8-K: Arvinas Presents Positive Phase 1 Data for Oral PROTAC ARV-102 in Healthy Volunteers, Showing Blood-Brain Barrier Penetration and LRRK2 Degradation

Arvinas announced positive first-in-human clinical trial data for ARV-102, an investigational PROTAC LRRK2 degrader, demonstrating blood-brain barrier penetration and substantial LRRK2 reduction in healthy volunteers.

Summary

• Arvinas presented data from a Phase 1 clinical trial of ARV-102, an investigational PROTAC LRRK2 degrader, at the 2025 International Conference on Alzheimers and Parkinsons Diseases.
• The trial assessed the safety, pharmacokinetics, and pharmacodynamics of orally administered ARV-102 in healthy male volunteers.
• ARV-102 demonstrated substantial reduction of LRRK2 in cerebral spinal fluid (CSF), with a promising safety/tolerability profile.
• The SAD cohort evaluated ARV-102 doses ranging from 10 mg to 200 mg, while the MAD cohort evaluated doses ranging from 10 mg to 80 mg.
• The drug was generally safe and well-tolerated, with no serious adverse events reported.
• ARV-102 exposure in the CSF increased in a dose-dependent manner, indicating brain penetration.
• At single oral doses of at least 60 mg and repeated oral doses of at least 20 mg, ARV-102 achieved greater than 50% LRRK2 reduction in the CSF and greater than 90% LRRK2 reduction in peripheral blood mononuclear cells (PBMCs).
• Arvinas initiated dosing in the SAD cohort of a Phase 1 clinical trial with ARV-102 in patients with PD in the fourth quarter of 2024.
• The company expects to complete enrollment and present initial data from the ongoing SAD cohort and initiate the MAD cohort of the Phase 1 clinical trial in patients with PD in 2025.

Sentiment

Score: 8

Explanation: The document presents positive Phase 1 clinical trial data for ARV-102, showing promising safety, tolerability, brain penetration, and LRRK2 reduction. Management's comments are optimistic, and the company plans to continue the clinical program. However, it's still early-stage data, and further trials are needed.

Positives

• ARV-102 was generally safe and well-tolerated in healthy volunteers, with no serious adverse events reported.
• ARV-102 demonstrated brain penetration, with CSF levels increasing in a dose-dependent manner.
• The drug achieved significant LRRK2 reduction in both the CSF (greater than 50%) and peripheral blood mononuclear cells (greater than 90%) at specific doses.
• ARV-102 induced decreases in peripheral phospho-Rab10T73 and BMP in urine, indicating downstream LRRK2 pathway engagement.

Negatives

• Headache was reported as a treatment-related adverse event in 17.1% of treated individuals compared to 0% in the placebo group.
• Post lumbar puncture syndrome was observed in the treated cohort at a rate of 17.1%.

Risks

• The MAD cohort of the Phase 1 clinical trial is ongoing, and the data is not yet complete.
• The long-term efficacy and safety of ARV-102 in patients with Parkinsons disease and progressive supranuclear palsy are still unknown.
• The company's ability to successfully conduct and complete development for its product candidates, including ARV-102, is subject to various risks and uncertainties.

Future Outlook

Arvinas plans to continue the ARV-102 clinical program, building upon the body of evidence for this lead PROTAC degrader candidate in its neuroscience pipeline, and expects to complete enrollment and present initial data from the ongoing SAD cohort of the Phase 1 clinical trial in patients with PD and initiate the MAD cohort of the Phase 1 clinical trial in patients with PD, in 2025.

Management Comments

• Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas, stated that the ability of ARV-102 to cross the blood-brain barrier and degrade the LRRK2 protein offers a potentially transformative therapeutic approach in the treatment of devastating neurodegenerative diseases.
• Dr. Berkowitz believes these results support continuing the ARV-102 clinical program and building upon the body of evidence for this lead PROTAC degrader candidate in the neuroscience pipeline.

Industry Context

The development of ARV-102 as a PROTAC LRRK2 degrader is relevant to the broader industry trend of targeting protein degradation for therapeutic purposes, particularly in neurodegenerative diseases like Parkinsons disease and PSP, where LRRK2 dysfunction is implicated.

Comparison to Industry Standards

• Other companies are also developing LRRK2 inhibitors for Parkinsons disease, such as Denali Therapeutics (DNL) and Biogen (BIIB).
• However, ARV-102's approach as a PROTAC degrader, aiming to degrade the LRRK2 protein rather than just inhibit its activity, represents a novel approach compared to traditional kinase inhibitors.
• The brain penetration and LRRK2 reduction data in CSF are key differentiators for ARV-102, as many drugs struggle to effectively cross the blood-brain barrier.

Stakeholder Impact

• Positive results could benefit patients with Parkinsons disease and progressive supranuclear palsy by providing a new therapeutic option.
• Successful development of ARV-102 could increase shareholder value.
• The company's employees are impacted by the progress of the clinical program.

Next Steps

• Complete enrollment and present initial data from the ongoing SAD cohort of the Phase 1 clinical trial in patients with PD.
• Initiate the MAD cohort of the Phase 1 clinical trial in patients with PD in 2025.
• Continue investigation of ARV-102 in neurodegenerative diseases associated with LRRK2 and lysosome dysfunction.

Key Dates

Keywords

ARV-102, LRRK2, PROTAC, Parkinsons disease, Progressive supranuclear palsy, Neurodegenerative diseases, Clinical trial, Protein degradation, Arvinas